S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.29 (-1.17%)
MSFT   420.79 (-0.15%)
META   489.85 (-0.81%)
GOOGL   150.66 (-0.14%)
AMZN   181.35 (+0.85%)
TSLA   176.85 (-1.66%)
NVDA   905.92 (+0.38%)
NIO   4.59 (-1.71%)
AMD   182.39 (+1.56%)
BABA   72.33 (+1.03%)
T   17.55 (+0.00%)
F   13.18 (+0.92%)
MU   118.44 (-0.59%)
CGC   9.11 (-4.61%)
GE   176.24 (-2.15%)
DIS   122.76 (+1.47%)
AMC   3.77 (-13.13%)
PFE   27.86 (+0.29%)
PYPL   66.74 (+0.26%)
XOM   115.40 (+0.37%)
NASDAQ:HOWL

Werewolf Therapeutics (HOWL) Stock Price, News & Analysis

$6.45
+0.10 (+1.57%)
(As of 10:32 AM ET)
Today's Range
$6.24
$6.66
50-Day Range
$3.92
$7.91
52-Week Range
$1.57
$8.19
Volume
103,935 shs
Average Volume
255,052 shs
Market Capitalization
$275.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Werewolf Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
75.4% Upside
$11.33 Price Target
Short Interest
Healthy
1.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Werewolf Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.38) to ($1.60) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.43 out of 5 stars

Medical Sector

355th out of 939 stocks

Pharmaceutical Preparations Industry

159th out of 434 stocks

HOWL stock logo

About Werewolf Therapeutics Stock (NASDAQ:HOWL)

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

HOWL Stock Price History

HOWL Stock News Headlines

Werewolf Therapeutics (NASDAQ:HOWL) Shares Up 2.9%
Werewolf Therapeutics Inc HOWL
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Recap: Werewolf Therapeutics Q4 Earnings
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
HOWL Mar 2024 2.500 put
Werewolf Therapeutics, Inc. (HOWL)
Wolves howl in different accents
See More Headlines
Receive HOWL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HOWL
Fax
N/A
Employees
47
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$15.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+75.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,370,000.00
Net Margins
-187.37%
Pretax Margin
-187.37%

Debt

Sales & Book Value

Annual Sales
$19.94 million
Book Value
$3.08 per share

Miscellaneous

Free Float
31,583,000
Market Cap
$276.10 million
Optionable
Optionable
Beta
0.72
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Daniel J. Hicklin Ph.D. (Age 60)
    Founder, CEO, President, Secretary & Director
    Comp: $817.31k
  • Dr. Cynthia Seidel-Dugan Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $600.35k
  • Dr. Randi Isaacs M.D. (Age 68)
    Chief Medical Officer
    Comp: $637.15k
  • Mr. Timothy W. Trost CPA (Age 66)
    CFO, Treasurer & Assistant Secretary
    Comp: $511.88k
  • Dr. Chulani Karunatilake Ph.D. (Age 65)
    Chief Technology Officer
    Comp: $343.43k
  • Ms. Ellen A. Lubman M.B.A. (Age 47)
    Chief Business Officer

HOWL Stock Analysis - Frequently Asked Questions

Should I buy or sell Werewolf Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOWL shares.
View HOWL analyst ratings
or view top-rated stocks.

What is Werewolf Therapeutics' stock price target for 2024?

2 equities research analysts have issued 1 year price objectives for Werewolf Therapeutics' shares. Their HOWL share price targets range from $9.00 to $15.00. On average, they anticipate the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 75.4% from the stock's current price.
View analysts price targets for HOWL
or view top-rated stocks among Wall Street analysts.

How have HOWL shares performed in 2024?

Werewolf Therapeutics' stock was trading at $3.86 on January 1st, 2024. Since then, HOWL shares have increased by 67.4% and is now trading at $6.46.
View the best growth stocks for 2024 here
.

Are investors shorting Werewolf Therapeutics?

Werewolf Therapeutics saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 432,000 shares, a decrease of 7.1% from the February 29th total of 464,800 shares. Based on an average trading volume of 255,100 shares, the short-interest ratio is currently 1.7 days. Approximately 1.6% of the company's stock are short sold.
View Werewolf Therapeutics' Short Interest
.

When is Werewolf Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HOWL earnings forecast
.

How were Werewolf Therapeutics' earnings last quarter?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 187.37% and a negative trailing twelve-month return on equity of 32.25%.

When did Werewolf Therapeutics IPO?

Werewolf Therapeutics (HOWL) raised $101 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Werewolf Therapeutics' major shareholders?

Werewolf Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include PFM Health Sciences LP (8.53%), Vanguard Group Inc. (2.15%), Vanguard Group Inc. (2.04%), Bridgeway Capital Management LLC (0.21%), Dimensional Fund Advisors LP (0.17%) and Northern Trust Corp (0.14%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard.
View institutional ownership trends
.

How do I buy shares of Werewolf Therapeutics?

Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOWL) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners